Live video webcast with Walter Klemp, CEO
and Jonathan Foster, Executive VP
and CFO of Moleculin on Tuesday, October
25th at 12:00 PM
ET
HOUSTON,
Oct. 11,
2023 /PRNewswire/ -- Moleculin Biotech, Inc.,
(Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates targeting hard to treat tumors and viruses, today
announced that Walter Klemp,
President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief
Financial Officer of Moleculin, will participate at the
Virtual Investor Ask the CEO Conference on Tuesday, October 25, 2023 at 12:00 PM ET
The "Ask the CEO" conference is intended to
provide the investment community with access to ask their questions
directly to management. Investors and interested parties will have
the opportunity to submit questions live during the event.
Questions can also be pre-submitted leading up to the event through
virtualinvestorco.com/asktheceo-mbrx. Participating companies will
answer as many questions as possible during the event.
A live video webcast of the event will be
available on the Events page of the Investors section of
the Company's website (moleculin.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company with a growing pipeline, including Phase 2
clinical programs, for hard-to-treat tumors and viruses. The
Company's lead program, Annamycin is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
Additionally, the Company is developing WP1066,
an Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of COVID-19 and other viruses,
as well as cancer indications including brain tumors, pancreatic
and other cancers.
For more information about the Company, please
visit www.moleculin.com and connect on Twitter,
LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-ask-the-ceo-conference-301953440.html
SOURCE Moleculin Biotech, Inc.